Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 2;8(1):11.
doi: 10.1186/s40345-019-0174-8.

Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial

Sheng-Yu Lee  1   2   3   4 , Tzu-Yun Wang  4 , Shiou-Lan Chen  5 , Yun-Hsuan Chang  6 , Po-See Chen  4 , San-Yuan Huang  7 , Nian-Sheng Tzeng  7 , Liang-Jen Wang  8 , I-Hui Lee  4 , Kao-Ching Chen  4 , Yen-Kuang Yang  4 , Jau-Shyong Hong  9 , Ru-Band Lu  10   11   12
Affiliations

Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial

Sheng-Yu Lee et al. Int J Bipolar Disord. .

Abstract

Background: The aim of this study is to determine whether adding combination of agents with anti-inflammatory and neurotrophic effects is more efficacious than mood stabilizer alone in improving clinical symptoms, plasma brain-derived neurotrophic factor (BDNF), cytokine levels, and metabolic profiles in patients with bipolar spectrum disorder.

Methods: In a randomized, double-blind, controlled 12-week clinical trial, patients with moderate mood symptoms (HDRS ≥ 18 or YMRS ≥ 14) were recruited. The patients were randomly assigned to a group while still undergoing regular valproate (VPA) treatments: VPA + dextromethorphan (DM) (30 mg/day) + memantine (MM) (5 mg/day) (DM30 + MM5) (n = 66), VPA + DM (30 mg/day) (DM30) (n = 69), VPA + MM (5 mg/day) (MM5) (n = 66), or VPA + Placebo (Placebo) (n = 69). Symptom severity, immunological parameters [plasma tumor necrosis factor (TNF)-α and C-reactive protein (CRP)] and plasma brain-derived neurotrophic factor (BDNF) were regularly examined. Metabolic profiles [cholesterol, triglycerides, glycosylated hemoglobin (HbA1C), fasting serum glucose, body mass index (BMI)] were measured at baseline and at 2, 8, and 12 weeks.

Results: Depression scores were significantly (P = 0.03) decreases and BDNF levels significantly (P = 0.04) increased in the DM30 + MM5 group than in the Placebo group. However, neither depressive scores nor BDNF levels were significantly different between the DM30, MM5, and Placebo groups. Changes in certain plasma cytokine and BDNF levels were significantly correlated with metabolic parameters.

Conclusion: We concluded that add-on DM30 + MM5 was significantly more effective than placebo for clinical symptoms and plasma BDNF levels. Additional studies with larger samples and mechanistic studies are necessary to confirm our findings. Trial registration NCT03039842 (https://register.clinicaltrials.gov/). Trial date was from 1 Jan 2013 to 31 December 2016 in National Cheng Kung University Hospital. Registered 28 February 1 2017-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03039842?term=NCT03039842&rank=1.

Keywords: BDNF; Bipolar II disorder; Bipolar spectrum disorder; Cytokines; Dextromethorphan; Memantine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
CONSORT diagram
Fig. 2
Fig. 2
a Difference in symptoms of depression in BD-II patients taking add-on DM30, MM5, and DM30 + MM5 versus placebo. b Difference in plasma BDNF levels in BD-II patients taking add-on DM30, MM5, and DM30 + MM5 versus placebo
Fig. 3
Fig. 3
a Survival curve of time to response in BD-II patients taking add-on DM30, MM5, and DM30 + MM5 versus placebo. b Survival curve of time to response in BD-II patients taking add-on DM30, MM5, and DM30 + MM5 versus placebo
See this image and copyright information in PMC

References

    1. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804–817. doi: 10.1016/j.neubiorev.2010.10.001. - DOI - PubMed
    1. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res. 2004;146:279–289. doi: 10.1016/S0079-6123(03)46018-4. - DOI - PubMed
    1. Chen JJ. Pharmacologic safety concerns in Parkinson’s disease: facts and insights. Int J Neurosci. 2011;121(Suppl 2):45–52. doi: 10.3109/00207454.2011.620193. - DOI - PubMed
    1. Chen SL, Lee SY, Chang YH, Chen PS, Lee IH, Wang TY, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol. 2014;24(11):1753–1759. doi: 10.1016/j.euroneuro.2014.09.001. - DOI - PubMed
    1. Cirulli F, Francia N, Branchi I, Antonucci MT, Aloe L, Suomi SJ, et al. Changes in plasma levels of BDNF and NGF reveal a gender-selective vulnerability to early adversity in rhesus macaques. Psychoneuroendocrinology. 2009;34(2):172–180. doi: 10.1016/j.psyneuen.2008.08.020. - DOI - PMC - PubMed

Associated data